Phase III Data Support Chemo-Free Approach to ALL

In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings could change the standard of care for the disease.

Publication Details

Journal
Cancer Discovery
Published
2025-12-09
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0110
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase III Data Support Chemo-Free Approach to ALL

Cancer Discovery
Chronic Myeloid Leukemia Treatments
article

Phase III Data Support Chemo-Free Approach to ALL

article en

Abstract

In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings could change the standard of care for the disease.

Cancer DiscoveryVol. 16(1)
Openalex Percentile: Top 39%
Chronic Myeloid Leukemia Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Phase III Data Support Chemo-Free Approach to ALL · Cancer Discovery (2025) | TGRS Research Map | TGRS